ORMP — Oramed Pharmaceuticals Income Statement
0.000.00%
- $104.42m
- -$41.06m
- $1.34m
- 62
- 40
- 69
- 58
Annual income statement for Oramed Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.7 | 2.71 | 2.7 | 2.7 | 1.34 |
Cost of Revenue | |||||
Gross Profit | 2.61 | 2.71 | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 17.3 | 14.5 | 26.9 | 43.3 | 17.1 |
Operating Profit | -14.6 | -11.8 | -24.2 | -40.6 | -15.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -14.1 | -11.5 | -23 | -37.7 | 5.09 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.4 | -11.5 | -23 | -37.8 | 5.09 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -14.4 | -11.5 | -22.2 | -36.6 | 5.53 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.4 | -11.5 | -22.2 | -36.6 | 5.53 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.822 | -0.561 | -0.781 | -0.938 | 0.136 |